vedolizumab
Takeda’s subcutaneous vedolizumab nabs CHMP nod for maintenance of ulcerative colitis and Crohn’s
February 28, 2020Medical Communications, Sales and Marketing CHMP, EMA, Takeda, vedolizumab
Takeda’s subcutaneous formulation of its gut-selective biologic vedolizumab has secured recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal …
Takeda’s subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis
October 22, 2018Sales and Marketing Takeda, UC, biologic, phase III, results, ulcerative colitis, vedolizumab
Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …
Takeda gets NICE nod for bowel treatment
March 13, 2015Sales and Marketing NHS, NICE, Takeda, enyyvio, vedolizumab
Takeda’s Entyvio becomes the first NICE approved gut-selective treatment for UK patients with ulcerative colitis (UC) – a long-term condition …
NICE rejects Takeda Crohn’s disease drug
December 23, 2014Sales and Marketing Crohn’s disease, Entyvio, NHS, NICE, Takeda, crohn's disease, vedolizumab
Takeda has seen its treatment for people with Crohn’s disease Entyvio rejected by NICE in an initial appraisal. The healthcare …
Latest content
Scots neonatal innovations target hearing loss and earlier care
August 28, 2026
Agentis Health Group acquires Clinical Pharmacist Solutions
August 26, 2026
